文献速递骨软组织肉瘤与黑色素瘤

MAPK通路的內质网转位驱动BRAF突变黑色素瘤的治疗耐药

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
PubMed 文献 · Cancer Discov · 2018-12-18

研究在BRAF突变黑色素瘤细胞中发现,BRAF抑制剂联合MEK抑制剂(BRAFi+MEKi)经GRP78和KSR2诱导SEC61依赖的MAPK通路内质网转位,进而导致ERK再激活和自噬;抑制内质网转位可阻断上述过程。耐药患者肿瘤中可检测到GRP78上调和ATF4磷酸化,耐药患者来源异种移植瘤中亦证实MAPK通路内质网转位。

要点

  • BRAFi+MEKi经GRP78和KSR2诱导SEC61依赖的MAPK通路内质网转位。
  • 抑制内质网转位可阻止ERK再激活与自噬,转位后ERK出内质网并被PERK再磷酸化。
  • 耐药患者肿瘤中GRP78上调和ATF4磷酸化,耐药PDX中可见MAPK通路内质网转位。

核心结论

  • BRAFi+MEKi诱导的MAPK通路内质网转位是ERK再激活所必需,并驱动自噬,从而连接两条主要耐药途径。
  • 该内质网转位机制是可成药的靶向治疗耐药驱动因素,抑制相关靶点可能增强对BRAFi+MEKi的应答。

研究设计与样本

  • 在BRAF突变黑色素瘤细胞中开展的机制研究,并检测耐药患者肿瘤与耐药患者来源异种移植瘤(PDX)。
  • 体内实验使用表达显性负性ATF4突变体的模型评估对BRAFi+MEKi的敏感性。

主要发现

  • BRAFi+MEKi经GRP78和KSR2诱导SEC61依赖的MAPK通路内质网转位。
  • 抑制内质网转位阻止ERK再激活和自噬;转位后ERK离开内质网并被PERK再磷酸化。
  • 再激活的ERK磷酸化ATF4,进而激活细胞保护性自噬。
  • 耐药患者肿瘤中检测到GRP78上调和ATF4磷酸化;耐药PDX中证实MAPK通路内质网转位。
  • 表达显性负性ATF4突变体在体内赋予对BRAFi+MEKi的敏感性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to BRAF and MEK inhibitors (BRAFi + MEKi) in BRAF-mutant tumors occurs through heterogeneous mechanisms, including ERK reactivation and autophagy. Little is known about the mechanisms by which ERK reactivation or autophagy is induced by BRAFi + MEKi. Here, we report that in BRAF-mutant melanoma cells, BRAFi + MEKi induced SEC61-dependent endoplasmic reticulum (ER) translocation of the MAPK pathway via GRP78 and KSR2. Inhibition of ER translocation prevented ERK reactivation and autophagy. Following ER translocation, ERK exited the ER and was rephosphorylated by PERK. Reactivated ERK phosphorylated ATF4, which activated cytoprotective autophagy. Upregulation of GRP78 and phosphorylation of ATF4 were detected in tumors of patients resistant to BRAFi + MEKi. ER translocation of the MAPK pathway was demonstrated in therapy-resistant patient-derived xenografts. Expression of a dominant-negative ATF4 mutant conferred sensitivity to BRAFi + MEKi in vivo. This mechanism reconciles two major targeted therapy resistance pathways and identifies druggable targets, whose inhibition would likely enhance the response to BRAFi + MEKi. SIGNIFICANCE: ERK reactivation and autophagy are considered distinct resistance pathways to BRAF + MEK inhibition (BRAFi + MEKi) in BRAF V600E cancers. Here, we report BRAFi + MEKi-induced ER translocation of the MAPK pathway is necessary for ERK reactivation, which drives autophagy. The ER translocation mechanism is a major druggable driver of resistance to targeted therapy.This article is highlighted in the In This Issue feature, p. 305.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Ojha R, Leli NM, Onorati A, et al. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov. 2018. PMID: 30563872. doi:10.1158/2159-8290.CD-18-0348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。